A randomized screening trial was started in Europe to show the effect of early detection and treatment of prostate cancer on mortality (European Study on Screening of Prostate Cancer). In one centre (Rotterdam), the screening protocol initially consisted of 3 screening tests for all men: prostate-sp
The European randomized study of screening for prostate cancer : An update
β Scribed by Bo Standaert; Louis Denis
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 87 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
A consensus meeting on screening and global strategy for prostate carcinoma, held in antwerp in 1994, determined the willingness among european cancer prevention centers to pursue vigorously the collaborative formation of a multinational randomized screening trial. this trial was to be named the european randomized study of screening for prostate cancer (erspc).
Methods:
During the years prior to that meeting, several feasibility trials were conducted in antwerp and rotterdam to evaluate the pitfalls and problems of a randomized procedure for population screening. today, five centers in five european countries share their study work and results via the erspc, and others are lining up to join this massive effort. regular meetings and specific work groups enable the research centers to compare their data, because the trial methodology differs slightly from one center to another.
Results:
However, a common work strategy and analysis of the data has recently been reached, and the first study results of the trial (evaluating 180,000 men over a 10-year screening period) are expected by the year 2007.
Conclusions:
A randomized trial of prostate carcinoma screening is set up in europe currently with five participating centers from five countries. first overall effect results of regular screening are expected after a 10-year period of follow-up.
π SIMILAR VOLUMES
In the European Randomized Study of Screening for Prostate Cancer (ER-SPC, Rotterdam region), men aged 55-74 years are screened for prostate cancer by prostatespecific antigen (PSA) sampling, digital rectal examination (DRE), and transrectal ultrasound investigation (TRUS). All men with a PSA Υ4 ng/
Variance estimators are derived for estimators of the average lead time and average benefit time due to screening in a randomized screening trial via influence functions. The influence functions demonstrate that these estimators are asymptotically equivalent to the mean difference, between the study
after lung cancer. 1 Prostate cancer accounts for 36% of all male can-Nancy Lins 5 cers in the United States and 13% of male cancer-related deaths. The incidence of prostate cancer is 66% higher among African-American
Prostate cancer is the most commonly diagnosed malignancy among men in the United States. Radical prostatectomy has been the gold standard for treating clinically localized prostate cancer. Its morbidity and disease-control capabilities have been well studied. At 10 years after surgery, 50% to 70% o
## Background: The 46,193 men aged 45 to 80 years registered in the electoral roll of quebec city and its metropolitan area were randomized in november 1988 between screening and no screening in a study aimed of assessing the impact of prostate cancer screening on cause-specific death. ## Methods: